<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499551</url>
  </required_header>
  <id_info>
    <org_study_id>Iontophoresis001</org_study_id>
    <nct_id>NCT00499551</nct_id>
  </id_info>
  <brief_title>A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis</brief_title>
  <official_title>A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The multiple properties of the corticosteroids over the inflammatory response, make them&#xD;
      first line drugs for the treatment of several ocular inflammatory disorders of different&#xD;
      etiologies. In order to diminish the corticosteroids severe systemic adverse effects, the&#xD;
      local administration is preferred. Iontophoresis already has been used in a successful way&#xD;
      for the administration of corticosteroids. Clinical or histopathological injuries due to the&#xD;
      use of transcleral CCI have not been observed. being successful the administration of&#xD;
      methylprednisolone by means of this system in previous studies. The objective is to evaluate&#xD;
      the tolerance, security and effectiveness of this treatment, using a new generation device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The multiple properties of the corticosteroids on the inflammatory response, make them a&#xD;
      first line election in the treatment of several ocular inflammatory disorders of different&#xD;
      etiologies. Within its properties we can mention: the reestablishment of the vascular&#xD;
      permeability, decrease of the cellular infiltrated and the exudation of fibrin, alteration of&#xD;
      the activity of monocytes and neutrophils, decrease the proliferation of fibroblasts and&#xD;
      endothelial cells and diminish the neovascularization post inflammation (1). For that reason,&#xD;
      not only they diminish the inflammatory reaction, but they also diminish the formation of&#xD;
      permanent scar, that often is responsible for the visual loss (2,3).&#xD;
&#xD;
      The most severe systemic adverse effects of the corticosteroids are: systemic hyperglicemy,&#xD;
      the formation of gastric ulcers, avascular necrosis to of the head of the femur, suppression&#xD;
      of the hypothalamus-pituitary adrenal axis, arterial hypertension among others (21,22). In&#xD;
      order to diminish the severe systemic adverse effects of the corticosteroids, the local&#xD;
      administration is preferred (4). The subconjunctival injection or topical instillation,&#xD;
      reaches effective concentrations in the anterior chamber (5-7) whereas to reach these&#xD;
      concentrations in the posterior segment it requires a systemic, intravitreous or periocular&#xD;
      administration (8-11). Generally it require multiple injections, which produces patient&#xD;
      discomfort. In addition, after periocular administration, just a small fraction of the drug&#xD;
      penetrates the eye, whereas the rest is systemically absorbed, reason why the systemic&#xD;
      adverse effects are not avoided.&#xD;
&#xD;
      Iontophoresis already has been successful used for the administration of corticosteroids,&#xD;
      reaching high and lasting concentrations in both segments of the eye. (12-13). Remaining with&#xD;
      effective concentrations up to 40 to 60 hours after the administration (23). But, Because&#xD;
      focal chorioretinal injuries have been described, with the use of transcleral Iontophoresis,&#xD;
      using current of high densities (14-18), this method has not gain a space in the current&#xD;
      clinical practice. It has been previously demonstrated that the Controlled Column&#xD;
      Iontophoresis (CCI Eyegate, Optis France SA) was as effective as the intraperitoneal&#xD;
      administration of Dexamethasone for the treatment of the anterior and posterior uveitis&#xD;
      induced by endotoxins (19). Through control of the electrical parameters and using safer&#xD;
      settings, clinical or histopathological injuries due to the use of transcleral CCI have not&#xD;
      been observed (20). The results of a pre-clinical study, in which methylprednisolone&#xD;
      succinate by means of CCI was administered, demonstrated to be a safe method, reporting high&#xD;
      and lasting intraocular concentrations.&#xD;
&#xD;
      In addition, a study in France was elaborated, that included 89 patients with different&#xD;
      intraocular inflammatory diseases. Such as corneal graft rejections, previous uveitis,&#xD;
      postoperative endophthalmitis, macular edema and inflammations of the posterior segment. For&#xD;
      the evaluation of the security and effectiveness of the administration of methylprednisolone&#xD;
      by means of CCI. The patients were enlisted if they required periocular or systemic treatment&#xD;
      due to the failure of maximal topical therapy. The average of treatment with Iontophoresis&#xD;
      was of 2,7 +/- 0,9 (1-5), with an current intensity of 1,2 to 2mA and duration of 2 to 5&#xD;
      minutes of each treatment.&#xD;
&#xD;
      A significant increase of conjunctival hyperemia was observed, subsequent to each CCI, which&#xD;
      spontaneous resolved. There were no related adverse Effects. Still more, it was observed an&#xD;
      increase of the visual acuity and decrease of the clinical inflammation in this group of&#xD;
      patients. No of the patients loss vision and the inflammation biomarkers, taken like a whole,&#xD;
      continued improving up to 30 days after the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The drug needed for the study is not available in Mexico anymore.&#xD;
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the tolerance, security and effectiveness in the treatment of different intraocular inflammatory disease</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish the Iontophoresis utility in the drug administration in the treatment of the IID</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the effectiveness of the CCI with Dexamethasone in the IID control</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the security of the Dexamethasone administration with CCI in the treatment of the IID</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the time in which the control of the ocular inflammation is succeed when using the CCI with Dexamethasone.</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Uveitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iontophoresis second generation Eyegate II device</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical history of, none-infectious anterior, intermediate, posterior or panuveitis,&#xD;
             with or without associate systemic disease, like: Vogt Koyanagi Harada, Wegener&#xD;
             Granulomatosis, Systemic erythematous Lupus, Behçet disease, etc.&#xD;
&#xD;
          -  Requirement or with current topical treatment with steroids (more than every 6 hours),&#xD;
             needs acute or chronic treatment with oral, intravenous, periocular or intravitreous&#xD;
             corticosteroids or immunosuppressive agents for the control of the disease.&#xD;
&#xD;
          -  Best Corrected Visual Acuity in the worse eye of 20/40 to 20/800 in ETDRS record.&#xD;
&#xD;
          -  Patients with good mydriasis and no significant ocular opacities.&#xD;
&#xD;
          -  Patients who do not plan elective surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infectious, pos-traumatic, Fuchs or self-limited uveitis. Patients with Diagnosis of&#xD;
             glaucoma or ocular hypertension (greater than 25mmHg).&#xD;
&#xD;
          -  Diagnosis or suspects ocular or central nervous system lymphoma. Patients with only&#xD;
             one eye.&#xD;
&#xD;
          -  Associated optical Neuritis of any etiology.&#xD;
&#xD;
          -  Severe injuries in the eyelids or in the ocular surface that prevent the application&#xD;
             of the electrode.&#xD;
&#xD;
          -  Well-known allergy to the Dexamethasone.&#xD;
&#xD;
          -  Toxoplasma scar or vitreous hemorrhage.&#xD;
&#xD;
          -  Corneal injuries of herpetic origin or with suspicion of being herpetic.&#xD;
&#xD;
          -  Patients with poor mydriasis, significant ocular opacities that prevents the&#xD;
             evaluation of the posterior pole or the follow-up studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lourdes Arellanes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul Velez-Montoya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Asociación para Evitar la Ceguera en Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Cole HP, Stallman J. Diamon DJ. High Dose Intravitreal Dexamethasone for Infections Endophthalmitis. Invest Ophthalmol Visc Sci. 1989;30:509-512.</citation>
  </reference>
  <reference>
    <citation>Schulman JA, Peyman GA. Intravitreal corticosteroids as an adjunct in the treatment of bacterial and fungal endophthalmitis. A review. Retina. 1992;12(4):336-40. doi: 10.1097/00006982-199212040-00007.</citation>
    <PMID>1485018</PMID>
  </reference>
  <reference>
    <citation>Stanbury RM, Graham EM. Systemic corticosteroid therapy--side effects and their management. Br J Ophthalmol. 1998 Jun;82(6):704-8. doi: 10.1136/bjo.82.6.704.</citation>
    <PMID>9797677</PMID>
  </reference>
  <reference>
    <citation>Leibowitz HM, Kupferman A. Periocular injection of corticosteroids: an experimental evaluation of its role in the treatment of corneal inflammation. Arch Ophthalmol. 1977 Feb;95(2):311-4. doi: 10.1001/archopht.1977.04450020112019.</citation>
    <PMID>836214</PMID>
  </reference>
  <reference>
    <citation>MCCARTNEY HJ, DRYSDALE IO, GORNALL AG, BASU PK. AN AUTORADIOGRAPHIC STUDY OF THE PENETRATION OF SUBCONJUNCTIVALLY INJECTED HYDROCORTISONE INTO THE NORMAL AND INFLAMED RABBIT EYE. Invest Ophthalmol. 1965 Jun;4:297-302. No abstract available.</citation>
    <PMID>14326615</PMID>
  </reference>
  <reference>
    <citation>Benson H. Permeability of the cornea to topically applied drugs. Arch Ophthalmol. 1974 Apr;91(4):313-27. doi: 10.1001/archopht.1974.03900060323017. No abstract available.</citation>
    <PMID>4621283</PMID>
  </reference>
  <reference>
    <citation>Barry A, Rousseau A, Babineau LM. The penetration of steroids into the rabbit's vitreous, choroid and retina following retrobulbar injection. I. Can J Ophthalmol. 1969 Oct;4(4):365-9. No abstract available.</citation>
    <PMID>5822457</PMID>
  </reference>
  <reference>
    <citation>Bodker FS, Ticho BH, Feist RM, Lam TT. Intraocular dexamethasone penetration via subconjunctival or retrobulbar injections in rabbits. Ophthalmic Surg. 1993 Jul;24(7):453-7.</citation>
    <PMID>8351091</PMID>
  </reference>
  <reference>
    <citation>Weijtens O, van der Sluijs FA, Schoemaker RC, Lentjes EG, Cohen AF, Romijn FP, van Meurs JC. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997 Mar;123(3):358-63. doi: 10.1016/s0002-9394(14)70131-x.</citation>
    <PMID>9063245</PMID>
  </reference>
  <reference>
    <citation>Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, van Meurs JC. Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol. 1998 May;125(5):673-9. doi: 10.1016/s0002-9394(98)00003-8.</citation>
    <PMID>9625551</PMID>
  </reference>
  <reference>
    <citation>Lachaud JP. [Considerations on the use of corticoids by ionization in certain ocular diseases]. Bull Soc Ophtalmol Fr. 1965 Jan;65(1):84-9. No abstract available. French.</citation>
    <PMID>5827464</PMID>
  </reference>
  <reference>
    <citation>Lam TT, Edward DP, Zhu XA, Tso MO. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol. 1989 Sep;107(9):1368-71. doi: 10.1001/archopht.1989.01070020438050.</citation>
    <PMID>2783069</PMID>
  </reference>
  <reference>
    <citation>Lam TT, Fu J, Tso MO. A histopathologic study of retinal lesions inflicted by transscleral iontophoresis. Graefes Arch Clin Exp Ophthalmol. 1991;229(4):389-94. doi: 10.1007/BF00170699. Erratum In: Graefes Arch Clin Exp Ophthalmol 1992;230(2):199.</citation>
    <PMID>1916328</PMID>
  </reference>
  <reference>
    <citation>Barza M, Peckman C, Baum J. Transscleral iontophoresis of cefazolin, ticarcillin, and gentamicin in the rabbit. Ophthalmology. 1986 Jan;93(1):133-9. doi: 10.1016/s0161-6420(86)33780-1.</citation>
    <PMID>3951811</PMID>
  </reference>
  <reference>
    <citation>Barza M, Peckman C, Baum J. Transscleral iontophoresis of gentamicin in monkeys. Invest Ophthalmol Vis Sci. 1987 Jun;28(6):1033-6.</citation>
    <PMID>3583629</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>July 8, 2008</last_update_submitted>
  <last_update_submitted_qc>July 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2008</last_update_posted>
  <keyword>Anterior Uveitis</keyword>
  <keyword>Posterior Uveitis</keyword>
  <keyword>Intermediate Uveitis</keyword>
  <keyword>Panuveitis</keyword>
  <keyword>Iontophoresis</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

